ArticleIBRO neuroscience reports2026
Pre-treatment cognitive impairment in patients with NSCLC: Prevalence and psychosocial factors.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer-related cognitive impairment (CRCI) is increasingly recognized in patients with non-central nervous system malignancies, including non-small cell lung cancer (NSCLC), although evidence on pre-treatment cognitive functioning and associated psychosocial factors remains limited. This exploratory study investigated baseline cognitive functioning in NSCLC patients before oncological treatment and examined the role of cognitive reserve, emotional distress, sleep quality, and subjective cognitive complaints. Methods: Fifty NSCLC patients underwent comprehensive neuropsychological and psychological assessment before treatment initiation. Cognitive functioning was evaluated through standardized tests assessing global cognition, executive functions, memory, attention/processing speed, and language. Cognitive impairment was classified according to International Cognition and Cancer Task Force criteria. Psychological measures included subjective cognitive complaints, depressive symptoms, anxiety, sleep quality, cognitive reserve, and quality of life. Associations with a Composite Cognitive Score (CCS) and domain-specific scores were examined using univariable linear regression analyses. Results: Eighteen patients (36%) met criteria for objective cognitive impairment at baseline. Higher cognitive reserve was associated with better global cognitive performance and stronger attention/processing speed and executive functioning. Conversely, depressive symptoms, anxiety, and poorer sleep quality were associated with lower CCS and worse performance across several domains, particularly global cognition, memory, and attention/processing speed. Subjective cognitive complaints showed partial concordance with objective cognitive performance. Conclusions: Cognitive impairment may already be present in a substantial proportion of NSCLC patients before treatment initiation. Early cognitive and psychosocial assessment may help identify patients at higher risk for CRCI and guide supportive interventions. These findings support early multidisciplinary screening strategies targeting vulnerable patients before treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.